(-)-epigallocatechin 3-gallate multiple interactions ISO RGD:1314216 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LATS2 mRNA CTD PMID:22079256 (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of LATS2 mRNA CTD PMID:25729387 (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE increases expression EXP 6480464 Topotecan results in increased expression of LATS2 mRNA CTD PMID:25729387 17beta-estradiol decreases expression ISO RGD:1314216 6480464 Estradiol results in decreased expression of LATS2 mRNA CTD PMID:24758408 2,2',4,4'-Tetrabromodiphenyl ether increases expression ISO RGD:1314216 6480464 2 more ... CTD PMID:19095052 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1314217 6480464 Tetrachlorodibenzodioxin affects the expression of LATS2 mRNA CTD PMID:21570461 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione increases expression ISO RGD:1314216 6480464 Thalidomide analog results in increased expression of LATS2 mRNA CTD PMID:20525221 2-methoxyethanol increases expression EXP 6480464 methyl cellosolve results in increased expression of LATS2 mRNA CTD PMID:21061450 4-hydroxyphenyl retinamide decreases expression ISO RGD:1314217 6480464 Fenretinide results in decreased expression of LATS2 mRNA CTD PMID:28973697 6-propyl-2-thiouracil increases expression EXP 6480464 Propylthiouracil results in increased expression of LATS2 mRNA CTD PMID:24780913 aflatoxin B1 increases expression ISO RGD:1314217 6480464 Aflatoxin B1 results in increased expression of LATS2 mRNA CTD PMID:19770486 aflatoxin B1 decreases methylation ISO RGD:1314216 6480464 Aflatoxin B1 results in decreased methylation of LATS2 intron CTD PMID:30157460 aflatoxin B2 increases methylation ISO RGD:1314216 6480464 aflatoxin B2 results in increased methylation of LATS2 intron CTD PMID:30157460 antirheumatic drug increases expression ISO RGD:1314216 6480464 Antirheumatic Agents results in increased expression of LATS2 mRNA CTD PMID:24449571 benzo[a]pyrene multiple interactions ISO RGD:1314217 6480464 Benzo(a)pyrene promotes the reaction [AHR protein binds to LATS2 promoter] CTD PMID:19654925 benzo[a]pyrene affects methylation ISO RGD:1314216 6480464 Benzo(a)pyrene affects the methylation of LATS2 intron CTD PMID:30157460 benzo[a]pyrene diol epoxide I decreases expression ISO RGD:1314216 6480464 7 more ... CTD PMID:19150397 , PMID:20018196 bisphenol A affects expression ISO RGD:1314216 6480464 bisphenol A affects the expression of LATS2 mRNA CTD PMID:20170705 bisphenol A increases methylation EXP 6480464 bisphenol A results in increased methylation of LATS2 gene CTD PMID:28505145 bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of LATS2 mRNA CTD PMID:25181051 C60 fullerene decreases expression EXP 6480464 fullerene C60 results in decreased expression of LATS2 mRNA CTD PMID:19167457 carbamazepine affects expression ISO RGD:1314216 6480464 Carbamazepine affects the expression of LATS2 mRNA CTD PMID:25979313 carbon nanotube decreases expression ISO RGD:1314217 6480464 Nanotubes, Carbon analog results in decreased expression of LATS2 mRNA CTD PMID:25554681 choline multiple interactions ISO RGD:1314217 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of LATS2 gene CTD PMID:20938992 cisplatin decreases expression ISO RGD:1314216 6480464 Cisplatin results in decreased expression of LATS2 mRNA CTD PMID:27392435 cisplatin multiple interactions ISO RGD:1314216 6480464 [Cisplatin co-treated with jinfukang] results in decreased expression of LATS2 mRNA CTD PMID:27392435 copper atom multiple interactions ISO RGD:1314216 6480464 [NSC 689534 binds to Copper] which results in increased expression of LATS2 mRNA CTD PMID:20971185 copper atom decreases expression ISO RGD:1314216 6480464 Copper results in decreased expression of LATS2 protein CTD PMID:16246896 copper(0) multiple interactions ISO RGD:1314216 6480464 [NSC 689534 binds to Copper] which results in increased expression of LATS2 mRNA CTD PMID:20971185 copper(0) decreases expression ISO RGD:1314216 6480464 Copper results in decreased expression of LATS2 protein CTD PMID:16246896 copper(2+) multiple interactions ISO RGD:1314216 6480464 [NSC 689534 binds to Copper] which results in increased expression of LATS2 mRNA CTD PMID:20971185 copper(2+) decreases expression ISO RGD:1314216 6480464 Copper results in decreased expression of LATS2 protein CTD PMID:16246896 copper(II) sulfate increases expression ISO RGD:1314216 6480464 Copper Sulfate results in increased expression of LATS2 mRNA CTD PMID:19549813 crocidolite asbestos increases expression ISO RGD:1314216 6480464 Asbestos, Crocidolite results in increased expression of LATS2 mRNA CTD PMID:18687144 CU-O LINKAGE increases expression ISO RGD:1314216 6480464 cupric oxide results in increased expression of LATS2 mRNA CTD PMID:22077320 cyclosporin A decreases expression ISO RGD:1314217 6480464 Cyclosporine results in decreased expression of LATS2 mRNA CTD PMID:19770486 cyclosporin A decreases expression ISO RGD:1314216 6480464 Cyclosporine results in decreased expression of LATS2 mRNA CTD PMID:25562108 diazinon affects expression EXP 6480464 Diazinon affects the expression of LATS2 mRNA CTD PMID:22546817 dibutyl phthalate increases expression ISO RGD:1314217 6480464 Dibutyl Phthalate results in increased expression of LATS2 mRNA CTD PMID:17361019 , PMID:21266533 diuron decreases expression EXP 6480464 Diuron results in decreased expression of LATS2 mRNA CTD PMID:25152437 dorsomorphin multiple interactions ISO RGD:1314216 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LATS2 mRNA CTD PMID:27188386 doxorubicin increases expression ISO RGD:1314216 6480464 Doxorubicin results in increased expression of LATS2 mRNA CTD PMID:29803840 ethyl methanesulfonate increases expression ISO RGD:1314216 6480464 Ethyl Methanesulfonate results in increased expression of LATS2 mRNA CTD PMID:23649840 fenamidone increases expression ISO RGD:1314217 6480464 fenamidone results in increased expression of LATS2 mRNA CTD PMID:27029645 folic acid multiple interactions ISO RGD:1314217 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of LATS2 gene CTD PMID:20938992 formaldehyde increases expression ISO RGD:1314216 6480464 Formaldehyde results in increased expression of LATS2 mRNA CTD PMID:23649840 hydrogen peroxide affects expression ISO RGD:1314216 6480464 Hydrogen Peroxide affects the expression of LATS2 mRNA CTD PMID:20044591 L-methionine multiple interactions ISO RGD:1314217 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of LATS2 gene CTD PMID:20938992 menadione affects expression ISO RGD:1314216 6480464 Vitamin K 3 affects the expression of LATS2 mRNA CTD PMID:20044591 methyl methanesulfonate increases expression ISO RGD:1314216 6480464 Methyl Methanesulfonate results in increased expression of LATS2 mRNA CTD PMID:23649840 methylmercury chloride increases expression ISO RGD:1314216 6480464 methylmercuric chloride results in increased expression of LATS2 mRNA CTD PMID:28001369 N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine multiple interactions ISO RGD:1314216 6480464 TP53 mutant form inhibits the reaction [N more ... CTD PMID:18778698 N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine decreases expression ISO RGD:1314216 6480464 N more ... CTD PMID:18778698 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of LATS2 mRNA CTD PMID:25729387 oxaliplatin increases expression EXP 6480464 oxaliplatin results in increased expression of LATS2 mRNA CTD PMID:25729387 paracetamol affects expression ISO RGD:1314217 6480464 Acetaminophen affects the expression of LATS2 mRNA CTD PMID:17562736 phenobarbital affects expression ISO RGD:1314217 6480464 Phenobarbital affects the expression of LATS2 mRNA CTD PMID:23091169 potassium chromate multiple interactions ISO RGD:1314216 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LATS2 mRNA CTD PMID:22079256 potassium chromate increases expression ISO RGD:1314216 6480464 potassium chromate(VI) results in increased expression of LATS2 mRNA CTD PMID:22079256 SB 431542 multiple interactions ISO RGD:1314216 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LATS2 mRNA CTD PMID:27188386 silver atom increases expression ISO RGD:1314216 6480464 Silver results in increased expression of LATS2 mRNA CTD PMID:26014281 silver(0) increases expression ISO RGD:1314216 6480464 Silver results in increased expression of LATS2 mRNA CTD PMID:26014281 silver(1+) increases expression ISO RGD:1314216 6480464 Silver results in increased expression of LATS2 mRNA CTD PMID:26014281 tetrachloromethane affects expression ISO RGD:1314217 6480464 Carbon Tetrachloride affects the expression of LATS2 mRNA CTD PMID:17484886 thalidomide increases expression ISO RGD:1314216 6480464 Thalidomide analog results in increased expression of LATS2 mRNA CTD PMID:20525221 titanium dioxide decreases expression ISO RGD:1314217 6480464 titanium dioxide results in decreased expression of LATS2 mRNA CTD PMID:23557971 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of LATS2 mRNA CTD PMID:25729387 topotecan increases expression EXP 6480464 Topotecan results in increased expression of LATS2 mRNA CTD PMID:25729387 trichostatin A decreases expression ISO RGD:1314216 6480464 trichostatin A results in decreased expression of LATS2 mRNA CTD PMID:26272509 trichostatin A multiple interactions ISO RGD:1314216 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LATS2 mRNA CTD PMID:27188386 troglitazone increases expression ISO RGD:1314217 6480464 troglitazone results in increased expression of LATS2 mRNA CTD PMID:28973697 tungsten decreases expression ISO RGD:1314217 6480464 Tungsten results in decreased expression of LATS2 mRNA CTD PMID:30912803 tungsten(4+) decreases expression ISO RGD:1314217 6480464 Tungsten results in decreased expression of LATS2 mRNA CTD PMID:30912803 urethane increases expression ISO RGD:1314216 6480464 Urethane results in increased expression of LATS2 mRNA CTD PMID:28818685 valproic acid decreases expression ISO RGD:1314216 6480464 Valproic Acid results in decreased expression of LATS2 mRNA CTD PMID:23179753 valproic acid affects expression ISO RGD:1314216 6480464 Valproic Acid affects the expression of LATS2 mRNA CTD PMID:25979313 zinc atom multiple interactions ISO RGD:1314216 6480464 [PCI 5002 co-treated with Zinc] results in increased expression of LATS2 mRNA CTD PMID:18593933 zinc(0) multiple interactions ISO RGD:1314216 6480464 [PCI 5002 co-treated with Zinc] results in increased expression of LATS2 mRNA CTD PMID:18593933
Biological Process cellular protein localization ISO RGD:1314217 1624291 MGI:MGI:1333883 (MGI:MGI:3839170 , PMID:19289085) RGD MGI:MGI:3839170 , PMID:19289085 G1/S transition of mitotic cell cycle ISO RGD:1314216 1624291 (PMID:12853976) RGD PMID:12853976 G1/S transition of mitotic cell cycle IBA MGI:MGI:1354386 more ... 13792537 PMID:21873635 GO_Central G1/S transition of mitotic cell cycle ISO RGD:1314217 1624291 (MGI:MGI:3056218, PMID:15343267) RGD MGI:MGI:3056218 , PMID:15343267 hippo signaling ISO RGD:1314217 1624291 MGI:MGI:103262 more ... RGD MGI:MGI:3785211 , PMID:18369314 hippo signaling IBA MGI:MGI:1333883 more ... 13792537 PMID:21873635 GO_Central hippo signaling ISO RGD:1314216 1624291 (PMID:20412773) RGD PMID:20412773 hormone-mediated signaling pathway ISO RGD:1314216 1624291 (PMID:15131260) RGD PMID:15131260 hormone-mediated signaling pathway IEA UniProtKB:Q9NRM7 , ensembl:ENSP000003720351600115 GO_REF:0000107 Ensembl GO_REF:0000107 inner cell mass cell fate commitment ISO RGD:1314217 1624291 MGI:MGI:1333883 (MGI:MGI:5502808 , PMID:23824537) RGD MGI:MGI:5502808 , PMID:23824537 inner cell mass cellular morphogenesis ISO RGD:1314217 1624291 MGI:MGI:1333883 (MGI:MGI:5502808 , PMID:23824537) RGD MGI:MGI:5502808 , PMID:23824537 intracellular signal transduction ISO RGD:1314216 1624291 (PMID:10871863) RGD PMID:10871863 intracellular signal transduction IBA FB:FBgn0003744 more ... 13792537 PMID:21873635 GO_Central keratinocyte differentiation ISO RGD:1314217 1624291 MGI:MGI:103262 more ... RGD MGI:MGI:3785211 , PMID:18369314 negative regulation of canonical Wnt signaling pathway ISO RGD:1314217 1624291 MGI:MGI:88276 (MGI:MGI:4948149 , PMID:21512031) RGD MGI:MGI:4948149 , PMID:21512031 negative regulation of canonical Wnt signaling pathway IEA UniProtKB:Q9NRM7 , ensembl:ENSP000003720351600115 GO_REF:0000107 Ensembl GO_REF:0000107 negative regulation of canonical Wnt signaling pathway ISO RGD:1314216 1624291 (PMID:20412773) RGD PMID:20412773 negative regulation of cyclin-dependent protein serine/threonine kinase activity ISO RGD:1314216 1624291 (PMID:12853976) RGD PMID:12853976 negative regulation of cyclin-dependent protein serine/threonine kinase activity IEA UniProtKB:Q9NRM7 , ensembl:ENSP000003720351600115 GO_REF:0000107 Ensembl GO_REF:0000107 peptidyl-serine phosphorylation IBA MGI:MGI:87986 more ... 13792537 PMID:21873635 GO_Central positive regulation of apoptotic process IBA FB:FBgn0011739 , PANTHER:PTN002390470 13792537 PMID:21873635 GO_Central protein phosphorylation ISO RGD:1314217 1624291 (MGI:MGI:3839170, PMID:19289085) RGD MGI:MGI:3839170 , PMID:19289085 protein phosphorylation ISO RGD:1314216 1624291 (PMID:10871863) RGD PMID:10871863 regulation of organ growth ISO RGD:1314217 1624291 MGI:MGI:2654594 more ... RGD MGI:MGI:4948149 , PMID:21512031 regulation of organ growth IBA MGI:MGI:1354386 , PANTHER:PTN002390470 13792537 PMID:21873635 GO_Central Cellular Component centriolar satellite ISO RGD:1314216 1624291 RGD GO_REF:0000052 centriolar satellite IEA UniProtKB:Q9NRM7 , ensembl:ENSP000003720351600115 GO_REF:0000107 Ensembl GO_REF:0000107 centriolar satellite IEA UniProtKB:A0A024RDM3 , ensembl:ENSP000003720351600115 GO_REF:0000107 Ensembl GO_REF:0000107 cytosol IEA UniProtKB:A0A024RDM3 , ensembl:ENSP000003720351600115 GO_REF:0000107 Ensembl GO_REF:0000107 cytosol ISO RGD:1314216 1624291 RGD GO_REF:0000052 cytosol IEA UniProtKB:Q9NRM7 , ensembl:ENSP000003720351600115 GO_REF:0000107 Ensembl GO_REF:0000107 microtubule organizing center IEA UniProtKB:A0A024RDM3 , ensembl:ENSP000003720351600115 GO_REF:0000107 Ensembl GO_REF:0000107 microtubule organizing center IEA UniProtKB:Q9NRM7 , ensembl:ENSP000003720351600115 GO_REF:0000107 Ensembl GO_REF:0000107 nucleus ISO RGD:1314216 1624291 (PMID:10673337) RGD PMID:10673337 nucleus IBA PANTHER:PTN000500077 , UniProtKB:Q9NRM7 13792537 PMID:21873635 GO_Central spindle pole ISO RGD:1314216 1624291 (PMID:12853976) RGD PMID:12853976 spindle pole IBA MGI:MGI:1354386 more ... 13792537 PMID:21873635 GO_Central spindle pole ISO RGD:1314217 1624291 (MGI:MGI:3056218, PMID:15343267) RGD MGI:MGI:3056218 , PMID:15343267 Molecular Function ATP binding ISO RGD:1314216 1624291 (PMID:10871863) RGD PMID:10871863 ATP binding IEA UniProtKB:Q9NRM7 , ensembl:ENSP000003720351600115 GO_REF:0000107 Ensembl GO_REF:0000107 protein binding ISO RGD:1314216 1624291 UniProtKB:A6NIX2 more ... RGD PMID:16413547 more ... protein serine/threonine kinase activity ISO RGD:1314216 1624291 (PMID:10871863) RGD PMID:10871863 protein serine/threonine kinase activity IBA FB:FBgn0003091 more ... 13792537 PMID:21873635 GO_Central
Gene-Chemical Interaction Annotations
